Last updated on November 2018

Migraine - Clinical Trial for the Acute Treatment of Migraine Headache

Brief description of study

The primary purpose of this migraine study is to determine if the investigational medication, Rimegepan, is effective in comparison to placebo in the acute treatment of moderate to severe migraine headache.

After an initial 3-28 day screening period, qualified study participants will enter an up to 45 day treatment period. During this time, when participants experience a migraine headache of moderate to severe intensity, they will treat with the investigational medication (an orally disintegrating tablet) or placebo. Participants will record the severity of the migraine headache in a diary at specific time points from onset to post 48 hours. Participation includes 3 visits to the Summit Research Network in Portland, Oregon

Clinical Study Identifier: TX194518

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.